Wang Julia's most recent trade in Laboratory Corp. Of America Holdings was a trade of 7,800 Non-qualified Stock Options done . Disclosure was reported to the exchange on Feb. 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Labcorp | Julia Wang A. | Chief Financial Officer, EVP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 7,800 | 7,800 | - | - | Non-qualified Stock Options | |
| Labcorp | Julia Wang A. | Chief Financial Officer, EVP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 2,580 | 4,367 | - | - | Restricted Stock Unit | |
| Labcorp | Julia Wang A. | Chief Financial Officer, EVP | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 893 | 893 (0%) | 0% | - | Common Stock | |
| Labcorp | Julia Wang A. | Chief Financial Officer, EVP | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 893 | 1,787 | - | - | Restricted Stock Unit | |
| Labcorp | Julia Wang A. | Chief Financial Officer, EVP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 247.74 per share. | 06 Feb 2025 | 336 | 557 (0%) | 0% | 247.7 | 83,241 | Common Stock |
| Labcorp | Julia Wang | Chief Financial Officer, EVP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2024 | 8,100 | 8,100 | - | - | Non-qualified Stock Options | |
| Labcorp | Wang Julia | Chief Financial Officer, EVP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2024 | 2,680 | 2,680 | - | - | Restricted Stock Unit | |
| BeiGene Ltd - ADR | Julia Wang | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 143.90 per share. | 01 Jul 2024 | 472 | 0 (0%) | 0% | 143.9 | 67,919 | American Depositary Shares |
| BeiGene Ltd - ADR | Julia Wang | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 155.66 per share. | 24 Jun 2024 | 899 | 0 (0%) | 0% | 155.7 | 139,938 | American Depositary Shares |
| BeiGene Ltd - ADR | Julia Wang | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 159.74 per share. | 17 Jun 2024 | 314 | 0 (0%) | 0% | 159.7 | 50,159 | American Depositary Shares |
| BeiGene Ltd - ADR | Julia Wang | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 159.00 per share. | 17 Jun 2024 | 253 | 314 (0%) | 0% | 159 | 40,227 | American Depositary Shares |
| BeiGene Ltd - ADR | Julia Wang | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 158.58 per share. | 17 Jun 2024 | 195 | 567 (0%) | 0% | 158.6 | 30,924 | American Depositary Shares |
| BeiGene Ltd - ADR | Julia Wang | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 158.23 per share. | 17 Jun 2024 | 154 | 762 (0%) | 0% | 158.2 | 24,368 | American Depositary Shares |
| BeiGene Ltd - ADR | Julia Wang | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 256,659 | 256,659 | - | - | Share Option (Right to Buy) | |
| BeiGene Ltd - ADR | Julia Wang | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 136,240 | 456,326 (0%) | 0% | 0 | Ordinary Shares | |
| BeiGene Ltd - ADR | Julia Wang | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 167.08 per share. | 29 Feb 2024 | 397 | 0 (0%) | 0% | 167.1 | 66,331 | American Depositary Shares |